Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria.

BACKGROUND: Inflammatory bowel disease (IBD) increases the risk of colorectal cancer. Probiotic bacteria produce immunoregulatory metabolites in vitro such as conjugated linoleic acid (CLA), a polyunsaturated fatty acid with potent anti-carcinogenic effects. This study aimed to investigate the cellu...

Full description

Bibliographic Details
Main Authors: Josep Bassaganya-Riera, Monica Viladomiu, Mireia Pedragosa, Claudio De Simone, Raquel Hontecillas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3325233?pdf=render
_version_ 1818522291763412992
author Josep Bassaganya-Riera
Monica Viladomiu
Mireia Pedragosa
Claudio De Simone
Raquel Hontecillas
author_facet Josep Bassaganya-Riera
Monica Viladomiu
Mireia Pedragosa
Claudio De Simone
Raquel Hontecillas
author_sort Josep Bassaganya-Riera
collection DOAJ
description BACKGROUND: Inflammatory bowel disease (IBD) increases the risk of colorectal cancer. Probiotic bacteria produce immunoregulatory metabolites in vitro such as conjugated linoleic acid (CLA), a polyunsaturated fatty acid with potent anti-carcinogenic effects. This study aimed to investigate the cellular and molecular mechanisms underlying the efficacy of probiotic bacteria in mouse models of cancer. METHODOLOGY/PRINCIPAL FINDINGS: The immune modulatory mechanisms of VSL#3 probiotic bacteria and CLA were investigated in mouse models of inflammation-driven colorectal cancer. Colonic specimens were collected for histopathology, gene expression and flow cytometry analyses. Immune cell subsets in the mesenteric lymph nodes (MLN), spleen and colonic lamina propria lymphocytes (LPL) were phenotypically and functionally characterized. Mice treated with CLA or VSL#3 recovered faster from the acute inflammatory phase of disease and had lower disease severity in the chronic, tumor-bearing phase of disease. Adenoma and adenocarcinoma formation was also diminished by both treatments. VSL#3 increased the mRNA expression of TNF-α, angiostatin and PPAR γ whereas CLA decreased COX-2 levels. Moreover, VSL#3-treated mice had increased IL-17 expression in MLN CD4+ T cells and accumulation of Treg LPL and memory CD4+ T cells. CONCLUSIONS/SIGNIFICANCE: Both CLA and VSL#3 suppressed colon carcinogenesis, although VSL#3 showed greater anti-carcinogenic and anti-inflammatory activities than CLA. Mechanistically, CLA modulated expression of COX-2 levels in the colonic mucosa, whereas VSL#3 targeted regulatory mucosal CD4+ T cell responses.
first_indexed 2024-12-11T05:31:19Z
format Article
id doaj.art-778be9e6eccd45b5b2c609c101bf0954
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-11T05:31:19Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-778be9e6eccd45b5b2c609c101bf09542022-12-22T01:19:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3467610.1371/journal.pone.0034676Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria.Josep Bassaganya-RieraMonica ViladomiuMireia PedragosaClaudio De SimoneRaquel HontecillasBACKGROUND: Inflammatory bowel disease (IBD) increases the risk of colorectal cancer. Probiotic bacteria produce immunoregulatory metabolites in vitro such as conjugated linoleic acid (CLA), a polyunsaturated fatty acid with potent anti-carcinogenic effects. This study aimed to investigate the cellular and molecular mechanisms underlying the efficacy of probiotic bacteria in mouse models of cancer. METHODOLOGY/PRINCIPAL FINDINGS: The immune modulatory mechanisms of VSL#3 probiotic bacteria and CLA were investigated in mouse models of inflammation-driven colorectal cancer. Colonic specimens were collected for histopathology, gene expression and flow cytometry analyses. Immune cell subsets in the mesenteric lymph nodes (MLN), spleen and colonic lamina propria lymphocytes (LPL) were phenotypically and functionally characterized. Mice treated with CLA or VSL#3 recovered faster from the acute inflammatory phase of disease and had lower disease severity in the chronic, tumor-bearing phase of disease. Adenoma and adenocarcinoma formation was also diminished by both treatments. VSL#3 increased the mRNA expression of TNF-α, angiostatin and PPAR γ whereas CLA decreased COX-2 levels. Moreover, VSL#3-treated mice had increased IL-17 expression in MLN CD4+ T cells and accumulation of Treg LPL and memory CD4+ T cells. CONCLUSIONS/SIGNIFICANCE: Both CLA and VSL#3 suppressed colon carcinogenesis, although VSL#3 showed greater anti-carcinogenic and anti-inflammatory activities than CLA. Mechanistically, CLA modulated expression of COX-2 levels in the colonic mucosa, whereas VSL#3 targeted regulatory mucosal CD4+ T cell responses.http://europepmc.org/articles/PMC3325233?pdf=render
spellingShingle Josep Bassaganya-Riera
Monica Viladomiu
Mireia Pedragosa
Claudio De Simone
Raquel Hontecillas
Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria.
PLoS ONE
title Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria.
title_full Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria.
title_fullStr Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria.
title_full_unstemmed Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria.
title_short Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria.
title_sort immunoregulatory mechanisms underlying prevention of colitis associated colorectal cancer by probiotic bacteria
url http://europepmc.org/articles/PMC3325233?pdf=render
work_keys_str_mv AT josepbassaganyariera immunoregulatorymechanismsunderlyingpreventionofcolitisassociatedcolorectalcancerbyprobioticbacteria
AT monicaviladomiu immunoregulatorymechanismsunderlyingpreventionofcolitisassociatedcolorectalcancerbyprobioticbacteria
AT mireiapedragosa immunoregulatorymechanismsunderlyingpreventionofcolitisassociatedcolorectalcancerbyprobioticbacteria
AT claudiodesimone immunoregulatorymechanismsunderlyingpreventionofcolitisassociatedcolorectalcancerbyprobioticbacteria
AT raquelhontecillas immunoregulatorymechanismsunderlyingpreventionofcolitisassociatedcolorectalcancerbyprobioticbacteria